Sign in to continue:

Saturday, July 25th, 2026

Ausnutria Dairy Issues Profit Warning for HY2026: Anticipates Net Loss Amid Industry and Supply Chain Challenges





Ausnutria Dairy Corporation Ltd – Detailed Profit Warning Report (HY2026)

Ausnutria Dairy Corporation Ltd Issues Significant Profit Warning for HY2026

Key Highlights and Detailed Analysis for Investors

  • Sharp Decline in Revenue and Profit: Ausnutria Dairy Corporation Ltd expects its revenue for the first half of 2026 (HY2026) to be in the range of RMB3,065 million to RMB3,165 million, down considerably from RMB3,886.8 million in HY2025. More critically, the company anticipates a net loss of RMB685 million to RMB785 million for HY2026, compared to a net profit of RMB180.9 million in the prior period.
  • Core Business Remains Stable (Excluding One-Offs): Excluding one-time inventory-related adjustments, non-cash asset impairments, and other related impacts, the company’s core business fundamentals remained stable. The core net operating profit is expected to be RMB155 million to RMB255 million for HY2026, indicating the underlying business is still profitable despite headline losses.
  • Factors Behind the Weak Performance:
    • Industry and Supply Chain Challenges: The infant milk formula industry and international supply chain disruptions have adversely affected operations. Production bases in Europe suffered from logistics issues, rising transportation costs, and stricter regulatory requirements, impacting supply schedules and inventory turnover efficiency.
    • Proactive Channel & Inventory Adjustments: The company undertook a systematic review of channel inventories, leading to a one-off inventory-related adjustment. This has a short-term negative impact on profits but is intended to strengthen channel health and consumer experience for the long term.
    • Streamlining Operations and Asset Impairments: Focus on core brands and products led to SKU rationalisation, resource reallocation, and adjustments in overseas operations. As a result, temporary operating adjustment costs and non-cash asset impairments were recognised, further weighing on HY2026 results.
  • Strategic Response and Outlook: The company is strengthening supply chain management, optimising product portfolios, and focusing on the quality of channel operations. These actions are designed to improve operational efficiency and lay a solid foundation for long-term growth.
  • Share Repurchase Intentions: Amid recent capital market volatility and weak share performance, the Board intends to use its Share Repurchase Mandate (approved on 28 May 2026) to buy back shares at an appropriate time, subject to market conditions, regulations, and shareholder approval. This could support share value, but there is no guarantee on timing, quantity, or execution.
  • Share Repurchase Progress: As of the announcement date, the company has repurchased 911,000 shares under the mandate. Any further repurchases will be at the Board’s discretion.
  • Interim Results Disclosure: Detailed financial results for HY2026 will be announced on or before 26 August 2026. The figures provided are based on preliminary unaudited management accounts and may be subject to change.

Important Points for Shareholders

  • The sharp swing from profit to significant loss is a major event and likely to impact share price.
  • The losses are driven by a combination of industry headwinds, supply chain disruptions, and one-off accounting adjustments, not by deterioration in core operating performance.
  • The company’s intention to repurchase shares may offer some support to share price, but is not guaranteed.
  • Investors should be aware that the reported figures are preliminary and unaudited.
  • Shareholders are strongly advised to exercise caution when dealing in the shares due to the uncertain financial outlook and market volatility.

Board Composition

The Board includes Executive Directors (Ren Zhijian, Bartle van der Meer, Zhang Zhi), Non-Executive Directors (Han Shixiu, Yan Junrong, Zou Ying), and Independent Non-Executive Directors (Ma Ji, Chen Fuquan, Aidan Maurice Coleman).

Disclaimer

The information provided above is based on preliminary unaudited management accounts and other information currently available. It may be subject to further adjustments. Investors should not rely solely on this report and should consult official interim results and other disclosures prior to making investment decisions.




View AUSNUTRIA Historical chart here



CSPC Pharmaceutical Initiates Phase II Trial of SYH2070 Injection for Mixed Hyperlipidaemia in China 12

CSPC Pharmaceutical Group Initiates Phase II Clinical Trial ...

UBS AG Disclosure of Dealings in ENN Natural Gas Co Ltd Shares During Privatisation Scheme (March 2026)

Important Points for Shareholders and Potential Price Sensit...